Ai In Post Market Surveillance Market: Market Size & Forecast 2026

Post-market surveillance (PMS) using AI encompasses a range of technologies, including natural language processing, predictive analytics, and computer vision, that analyze real-world evidence from electronic health records, device registries, social media, and adverse event databases to identify safety signals earlier and more accurately than conventional approaches. The $1.712 billion global market size for 2026 reflects applications across pharmaceuticals, medical devices, combination products, and digital therapeutics, where regulators such as the U.S. FDA, EMA, and national authorities are mandating more rigorous post-approval monitoring. Unlike clinical-stage AI applications, PMS AI operates in a continuous, real-time data environment focused on risk detection, regulatory compliance, and lifecycle management of health products throughout their commercial use.

Stringent and evolving global regulatory frameworks are a primary catalyst, with bodies such as the FDA and EMA requiring manufacturers to implement more robust post-market monitoring programs and report adverse events in real time. The exponential growth of real-world data from electronic health records, wearable sensors, connected medical devices, and patient registries provides the raw material that AI systems require to identify safety signals faster and more comprehensively than manual review processes. Additionally, rising healthcare costs associated with product recalls, litigation, and delayed adverse event detection are compelling manufacturers and regulators to invest in proactive, AI-enabled surveillance platforms that can reduce risk and improve patient outcomes.

The market is segmented by product type, including medical devices, pharmaceuticals, and biologics, and by technology type, with natural language processing dominating due to its ability to extract insights from unstructured clinical text, followed by machine learning classification models and computer vision for imaging-based device monitoring. Deployment models span cloud-based platforms favored for scalability and data integration, and on-premise solutions preferred by organizations handling sensitive patient data under strict compliance regimes. Regionally, North America leads adoption due to the FDA's advanced regulatory framework, extensive digital health infrastructure, and concentration of major device and pharmaceutical manufacturers, while Europe follows closely behind driven by the EU Medical Device Regulation and pharmacovigilance requirements, and Asia-Pacific is emerging as the fastest-growing region due to expanding manufacturing sectors and improving regulatory frameworks and digital health infrastructure.